BioVie advances long COVID trial, top-line data expected by summer

BioVie CEO Cuong Do joined Steve Darling from Proactive to provide an update on the company’s ongoing clinical efforts targeting long COVID, a condition that continues to affect an estimated 17 million Americans despite the acute phase of the COVID-19 pandemic having subsided. Do emphasized that long COVID remains a significant and persistent public health challenge, with many patients experiencing debilitating symptoms such as brain fog, chronic fatigue, and general malaise that can severely impact daily functioning and quality of life. He noted that unlike the initial viral infection, long COVID appears to involve lingering viral protein fragments or related biological remnants that may continue to stimulate the immune system even after the virus has been cleared from the body. This ongoing immune activation is believed to contribute to sustained inflammation, which in turn may drive the neurological and systemic symptoms associated with the condition. BioVie Inc. is focusing its research efforts specifically on addressing these central nervous system-related symptoms through a targeted therapeutic approach. Do highlighted that the company’s program is supported by a $13 million clinical research grant, underscoring both the importance and urgency of developing effective treatments in this area. He also noted that BioVie is uniquely positioned in this space, stating that it is “the only company, nonprofit, any kind of organization to have received a grant to do this,” reinforcing the distinct nature of its clinical work. The company’s clinical trial is now nearing completion of patient enrollment, with top-line data expected by the end of the summer. This represents a key near-term milestone for the program as it moves toward evaluating efficacy and safety outcomes. Importantly, Do pointed out that there are currently no approved therapies specifically designed to treat long COVID, positioning BioVie’s program as a potential first-in-class treatment option in a space with significant unmet medical need. He expressed optimism about the trial’s progress and the potential impact of a successful outcome for patients who are still unable to return to normal daily activities or work due to lingering symptoms. proactiveinvestors #biovieince #nasdaq #bivi #LongCOVID #PostCOVID #ChronicFatigue #BrainFog #Neuroinflammation #ClinicalTrials #Biotech #CNSResearch #HealthcareInnovation #MedicalResearch #PublicHealth #Inflammation #DrugDevelopment #UnmetNeed